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Introduction {#sec001}
============

Currently, surgical resection using gastrectomy and proper perigastric lymphadenectomy is the only treatment option to enhance the survival rate of patients with gastric cancer \[[@pone.0114948.ref001]\]. Since the use of laparoscopic techniques for early gastric cancer was first reported in 1994 \[[@pone.0114948.ref002]\], laparoscopic gastrectomy (LG) for gastric cancer has become popular due to the many advantages of minimally invasive surgery and advances in surgical techniques \[[@pone.0114948.ref003]--[@pone.0114948.ref005]\]. However, LG is still classified as an investigational treatment in the most recent Japanese Guideline because of the lack of a prospective study with a sufficient sample size sufficient to prove its benefits \[[@pone.0114948.ref006]\]. On the other hand, in most countries, more than 80% of patients with gastric cancer are diagnosed with advanced gastric cancer (AGC). There is a lack of large-scale data concerning the long-term outcomes for these patients, so the use of LG for the treatment of AGC is still a contentious issue \[[@pone.0114948.ref007], [@pone.0114948.ref008]\]. Therefore, we present the usefulness of laparoscopic gastrectomy for gastric cancer based on our experience with over 2000 cases.

Patients and Methods {#sec002}
====================

Patients {#sec002a}
--------

Between January 2005 to October 2013, 3580 patients diagnosed with primary gastric cancer were treated with curative resection at the Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China. Of these patients, 2041 underwent a laparoscopic approach and 1539 patients underwent an open technique. Patients who diagnosed with cT1 to cT4a and without clinical evidence of extraperigastric lymph nodes and distant metastases were informed of the possible complications of the procedure and the advantages and disadvantages of a laparoscopic compared with an open approach. Written informed consent was obtained from all patients prior to the operation. A retrospective analysis was performed, using a prospectively maintained comprehensive database, to determine the technical pitfalls of the procedure. Patient demographics, underlying diseases, data on surgery, and data on preoperative and postoperative monitoring including complications and length of hospital stay were recorded in a clinical database system \[[@pone.0114948.ref009]\]. The surgical procedures were described in detail as follows: 1) total or subtotal gastrectomy was performed, according to tumor location, size, and depth of invasion. 2) D1+α (dissection of group 1 and number 7 lymph node), D1+β(dissection of group 1 and number 7, 8a, 9 lymph nodes), or D2 lymphadenectomy (dissection of all group 1 and group 2 lymph nodes) were undertaken according to the rules of the Japanese Research Society for Gastric Cancer \[[@pone.0114948.ref010]\]. The operation time was measured from the first skin incision to the closure of all skin incisions with skin staples. Staging was determined according to the 7th edition of the International Union against Cancer (UICC) TNM classification \[[@pone.0114948.ref011]\]. Adjuvant chemotherapy with 5-fluorouracil (5-FU)-based regimens (mostly 5-FU with cisplatin) was recommended to most patients with advanced gastric cancer.

Postoperative follow-ups were performed every 3 months for 2 years, and then every 6 months from 3 to 5 years. Most patients' routine follow-up appointments included a physical examination, laboratory tests (including CA19-9, CA72-4, and CEA levels), chest radiography, abdominopelvic ultrasonography or computed tomography (CT), and an annual endoscopic examination. If gastrointestinal symptoms were reported, an additional examination was carried out. The survival time was designated as the time from operation until the date that the survival information was collected or the date of death. All patients were observed until death or the final follow-up date of June 2014, whichever occurred first.

Ethics Statement {#sec002b}
----------------

Ethics committee of Fujian medical union hospital approved this retrospective study. Written consent was given by the patients for their information to be stored in the hospital database and used for research.

Statistical analysis {#sec002c}
--------------------

Statistical analysis was performed using SPSS.v16.0 for Windows (SPSS Inc., Chicago, IL). The statistical analysis was conducted by Student's t test or chi-square test, and cumulative survival was compared by Kaplan---Meier method and log rank test. Values of p \<0.05 were considered statistically significant.

Results {#sec003}
=======

Clinicopathological Characteristics of Patients {#sec003a}
-----------------------------------------------

The clinicopathological characteristics of the 3580 patients (2041 laparoscopic vs. 1539 open) are listed in [Table 1](#pone.0114948.t001){ref-type="table"}. There were 2693 males and 887 females whose ages ranged from 12 to 91 years (mean age was 60.5±11.1 years). For patients in the LG group, a distal gastrectomy was performed in 46.0% of patients, a total gastrectomy in 51.4%, and a proximal gastrectomy in 2.6% of patients. Meanwhile, for the OG group, a distal gastrectomy was performed in 42.4% of patients, a total gastrectomy in 54.5%, and a proximal gastrectomy in 3.1% of patients. According to the UICC TNM classification of gastric cancer \[[@pone.0114948.ref012]\], in LG group, 443 cases (21.7%) were at stage Ia, 155 cases (7.6%) at stage Ib, 218 cases (10.7%) at stage IIa, 237 cases (11.6%) at stage IIb, 216 cases (10.6%) at stage IIIa, 360 cases (17.6%) at stage IIIb, and 412 cases (20.2%) at stage IIIc. While, in the OG group, 227 cases (14.7%) were at stage Ia, 126 cases (8.2%) at stage Ib, 72 cases (4.7%) at stage IIa, 185 cases (12.0%) at stage IIb, 163 cases (10.6%) at stage IIIa, 264 cases (17.2%) at stage IIIb, and 502 cases (32.6%) at stage IIIc. There were more advanced gastric cancer in OG group than that in LG group (P\<0.001).

10.1371/journal.pone.0114948.t001

###### Clinicopathological Characteristics of patients (n = 3580).
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  **Characteristics**        **LG group (%, N = 2041)**   **OG group (%, N = 1539)**   **P value**
  -------------------------- ---------------------------- ---------------------------- -------------
  Age(years)                 61.0±11.1                    59.8±10.8                    0.643
  Gender                                                                               0.393
   Male                      1523 (74.6)                  1170 (76.0)                  
   Female                    518(25.4)                    369 (24.0)                   
  Performed operation                                                                  0.159
   Distal gastrectomy        938(46.0)                    652 (42.4)                   
   Total gastrectomy         1049(51.4)                   839 (54.5)                   
   Proximate gastrectomy     54(2.6)                      48 (3.1)                     
  Histologic type                                                                      \<0.0001
   Differentiated            384(18.8)                    397 (25.8)                   
   Undifferentiated          1657(81.2)                   1142 (74.2)                  
  Tumor diameter (cm)        4.6±2.6                      5.1±2.7                      0.005
  BMI（kg/m2）               22.3±3.2                     22.6±3.5                     0.734
  Tumor location                                                                       0.087
   Upper                     613(30.1)                    516(33.5)                    
   Middle                    470(23.0)                    338(22.0)                    
   Lower                     958(46.9)                    685(44.5)                    
  Depth of invasion                                                                    \<0.0001
   T1                        516(25.3)                    264(17.1)                    
   T2                        234(11.5)                    165(10.8)                    
   T3                        558(27.3)                    181(11.7)                    
   T4a                       733(36.0)                    929(60.4)                    
  pN stage                                                                             0.002
   N0                        779(38.2)                    504(32.7)                    
   N1                        287(14.1)                    208(13.5)                    
   N2                        351(17.2)                    260(16.9)                    
   N3a                       390(19.1)                    355(23.1)                    
   N3b                       234(11.5)                    212(13.8)                    
  TNM stage                                                                            \<0.0001
   Ia                        443(21.7)                    227(14.7)                    
   Ib                        155(7.6)                     126(8.2)                     
   IIa                       218(10.7)                    72(4.7)                      
   IIb                       237(11.6)                    185(12.0)                    
   IIIa                      216(10.6)                    163(10.6)                    
   IIIb                      360(17.6)                    264(17.2)                    
   IIIc                      412(20.2)                    502(32.6)                    
  Chemotherapy                                                                         0.037
   Yes                       1527(74.8)                   1246(81.0)                   
   No                        514(25.2)                    293(19.0)                    
  Vessel carcinoma embolus                                                             0.367
   Yes                       582(28.5)                    451(29.3)                    
   No                        1459(71.5)                   1088(71.7)                   

Perioperative and postoperative outcomes {#sec003b}
----------------------------------------

A conversion to open laparotomy was required in 18 patients (0.9%). The reasons for conversion were uncontrolled diffuse bleeding in the operation field for 13 cases, abdominal adhesions for 3 patients, and peripheral viscera injuries in 2 patients (one with a transverse colon injury and the other with a spleen injury). There were no significant differences in volume of operation time (P = 0.399), time to first flatus (P = 0.526), and time to resumption of diet (P = 0.649) between the two groups. However, the blood loss (P\<0.001), transfused patient number (P = 0.009), time to ground activities (P = 0.038), and post-operative hospital stay (P\<0.001) was significantly less in the LG group than those in the OG group.

One or more complications occurred in 277 patients (13.6%) of LG group and 221 patients (14.4%) of OG group without statistical significant (P\>0.05). Pulmonary problems were the most frequent in both two groups. Lymphorrhea, intraabdominal abscess, and wound infection were the most common problems in LG group with 38 (1.9%), 35 (1.7%), and 32 (1.6%) patients involved, respectively. While, wound infection, intraabdominal abscess, and lymphorrhea the most common problems in OG group. There were 6 patients (0.3%) in LG group who died by postoperative the 30^th^ day following the operation comprised 3 patients (0.2%) in OG group. The causes were anastomotic leakage and bleeding (3 patients), severe pneumonia (1 patient), disseminated intravascular coagulation (DIC) (1 patient), and infarct of spleen (1 patient) in LG group; in OG group there were two patients dead with anastomotic leakage and bleeding, one patient dead with pulmonary infection. ([Table 2](#pone.0114948.t002){ref-type="table"}).

10.1371/journal.pone.0114948.t002

###### Perioperative and postoperative results after laparoscopic and open gastrectomy.
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                                       **LG group (%)N = 2041**   **OG group (%)N = 1539**   **P value**
  ------------------------------------ -------------------------- -------------------------- -------------
  Conversion to open surgery           18 (0.9%)                  \-                         \-
  Operation time(min)                  189.5±56.8                 226.6±70.1                 0.399
  Blood loss(ml)                       75.2±111.4                 198.8±210.4                \<0.0001
  Transfused patients                  14 (0.7%)                  25(1.6%)                   0.009
  Time to ground activities (days)     2.3±0.7                    3.0±0.9                    0.038
  Time to first flatus (days)          3.7±0.9                    3.9±1.0                    0.526
  Time to resumption of diet (days)    4.8±1.1                    4.7±1.2                    0.649
  Postoperative hospital stay (days)   13.8±6.8                   15.1±8.3                   0.013
  Total complications                  277 (13.6)                 221(14.4)                  0.526
  Local complications                  218 (10.7)                 173(11.2)                  0.626
   Lymphorrhea                         38 (1.9)                   19(1.3)                    
   Intraabdominal abscess              35 (1.7)                   28(1.8)                    
   Wound infection                     32 (1.6)                   29(1.9)                    
   Anastomotic leakage                 24 (1.2)                   17(1.1)                    
   Intestinal obstruction              22 (1.1)                   18(1.2)                    
   Gastrasthenia                       21 (1.0)                   17(1.1)                    
   Abdominal bleeding                  14 (0.7)                   17(1.0)                    
   Anastomotic site bleeding           10 (0.5)                   9(0.6)                     
   Pancreatic fistula                  8 (0.4)                    9(0.6)                     
   Duodenal stump leakage              8 (0.4)                    5(0.3)                     
   Anastomotic straitly                5 (0.2)                    5(0.3)                     
   Infarct of spleen                   1 (0.05)                   0                          
  Systemic complications               59 (2.9)                   48(3.2)                    0.693
   Pneumonia                           48 (2.4)                   42(2.7)                    
   DIC                                 5 (0.2)                    0                          
   Blood poisoning                     4 (0.2)                    5(0.3)                     
   Cerebral infarction                 2 (0.1)                    1(0.1)                     
  Postoperative mortality              6 (0.3)                    3(0.2)                     0.740

Lymph node retrieval for LG and OG groups {#sec003c}
-----------------------------------------

The median number of retrieved LNs was 31 (range, 12--82; mean 31.1 ± 13.2) per patient. There was no significant difference in the total number of retrieved lymph nodes between the two groups (31.4±12.8 in the LG group vs 30.7±11.2 in the OG group; p = 0.445). According to the UICC TNM classification of gastric cancer, a comparative analysis of the total number of retrieved LNs showed no statistical significance for any of the stages of cancer, with the exception of stage IA, for which a more LNs was shown for the LG group. There were more positive LNs in OG group than that in LG group (6.6±8.5 vs. 5.7±8.2, P = 0.033). But there was no significant difference in the positive LNs at each stage between the two groups. ([Table 3](#pone.0114948.t003){ref-type="table"})

10.1371/journal.pone.0114948.t003

###### Lymph node retrieval for LG and OG groups.
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                         **LG group**   **OG group**   **P value**
  ---------------------- -------------- -------------- -------------
  No. of retrieved LNs   31.4±12.8      30.7±11.2      0.445
   Ia                    27.8±12.5      25.1±10.3      0.003
   Ib                    29.9±13.3      29.0±11.7      0.626
   IIa                   32.4±12.9      30.7±11.9      0.539
   IIb                   31.2±11.3      30.1±10.3      0.165
   IIIa                  32.2±11.4      31.6±11.0      0.225
   IIIb                  34.1±13.8      33.3±12.6      0.378
   IIIc                  35.6±12.4      34.5±10.9      0.134
  No. of positive LNs    5.7±8.2        6.6±8.5        0.033
   Ia                    0              0              \-
   Ib                    0.4±0.6        0.3±0.6        0.434
   IIa                   0.7±1.2        0.7±1.0        0.923
   IIb                   1.9±2.5        1.3±2.3        0.256
   IIIa                  4.0±3.2        3.6±2.9        0.677
   IIIb                  9.6±7.9        9.1±6.6        0.514
   IIIc                  15.4±8.6       16.2±8.7       0.165

Survival after the surgery {#sec003d}
--------------------------

During the follow-up stage, 81 patients in the LG group and 47 patients in the OG group were lost to follow-up. There were 456 patients in the laparoscopic group developed tumor recurrence, and the corresponding findings in the open group were 624 patients. The calculated 3-year disease-free survival (DFS) rate for all stages was 68.7% in the LG group and 61.4% in the OG group with significant difference (P\<0.05). While the calculated 3-year DFS rate for patients in stage Ia was 95.7% in the LG and 95.5% in the OG; in stage Ib, 92.8% and 95.0%; in stage IIA, 82.6% and 78.0%; in stage IIB, 77.9% and 75.5%; in stage IIIA, 68.8% and 62.2%; in stage IIIB, 50.2% and 53.4%; and in stage IIIC, 30.7% and 35.6%, respectively. A comparative analysis of the DFS showed no statistical significance for any of the stages of cancer ([Fig. 1](#pone.0114948.g001){ref-type="fig"}). Similar findings were observed for the 3-year overall survival (OS) rates. The actual 3-year OS rate was 71.2% in the LG and 62.6% in the OG for patients, which was statistically significant (P\<0.05). While the 3-year OS rate for stage IA was 97.0% in the LG group and 98.5% in the OG group; for stage IB, 93.0% and 97.0%; for stage IIA, 86.4% and 80.0%; for stage IIB, 78.8% and 77.9%; for stage IIIA, 70.2% and 64.3%; for stage IIIB, and 54.3% and 54.4%; for stage IIIC, 33.8% and 36.8%, respectively. Comparisons of the overall survival rates did not show statistical significance for any of the stages of cancer. ([Table 4](#pone.0114948.t004){ref-type="table"}, [Fig. 2](#pone.0114948.g002){ref-type="fig"}).

![Kaplan-Meier curves for DFS.\
Kaplan-Meier curves for DFS between the laparoscopic gastrectomy and open gastrectomy groups.](pone.0114948.g001){#pone.0114948.g001}

10.1371/journal.pone.0114948.t004

###### The calculated 3-year DFS rates and OS rates after laparoscopic and open gastrectomy.
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  **Stages**                                             **LG group (%)**   **OG group (%)**   **P value**
  ------------------------------------------------------ ------------------ ------------------ -------------
  3-year DFS[\*](#t004fn001){ref-type="table-fn"} rate   68.7               61.4               0.001
   Ia                                                    95.7               95.5               0.545
   Ib                                                    92.8               95.0               0.205
   IIa                                                   82.6               78.0               0.228
   IIb                                                   77.9               75.5               0.354
   IIIa                                                  68.8               62.2               0.189
   IIIb                                                  50.2               53.4               0.311
   IIIc                                                  30.7               35.6               0.344
  3-year OS[\*](#t004fn001){ref-type="table-fn"} rate    71.2               62.6               \<0.0001
   Ia                                                    97.0               98.5               0.360
   Ib                                                    93.0               97.0               0.107
   IIa                                                   86.4               80.0               0.106
   IIb                                                   78.8               77.9               0.421
   IIIa                                                  70.2               64.3               0.210
   IIIb                                                  54.3               54.4               0.903
   IIIc                                                  33.8               36.8               0.763

\*DFS: disease-free survival; OS: overall survival

![Kaplan-Meier curves for OS.\
Kaplan-Meier curves for OS between the laparoscopic gastrectomy and open gastrectomy groups.](pone.0114948.g002){#pone.0114948.g002}

Discussion {#sec004}
==========

Gastric cancer is one of the most common causes of cancer-related death in the world \[[@pone.0114948.ref012]\]. In most countries in the world, with exceptions including Japan and Korea, more than 80% of patients with gastric cancer are diagnosed with advance gastric cancer (AGC). Among the less invasive operations noted in recent years, laparoscopic gastrectomy for gastric cancer has become popular due to advances in surgical techniques. As experience with LG for early gastric cancer has accumulated, some centers have attempted to expand the indication of LG to AGC, and a few studies have already demonstrated that surgeons can safely perform laparoscopic gastrectomy in these cases with better qualities of life than those who underwent conventional open surgery \[[@pone.0114948.ref013]--[@pone.0114948.ref015]\]. But these retrospective studies of LG for AGC only included less advanced gastric cancer such as those at stage II or stage IIIa \[[@pone.0114948.ref016], [@pone.0114948.ref017]\]. The effects of LG for more advanced gastric cancer, such as stage IIIb and stage IIIc disease were rarely reported. In this study, we analyzed no only the early gastric cancer, but also some more advanced gastric cancer, and found that patients undergoing laparoscopic surgery had better postoperative recovery, with less blood loss, quicker intestinal functional recovery, and shorter hospital stay than those undergoing conventional open surgery too. Like the other laparoscopic procedures, there is a learning curve associated with laparoscopic gastrectomy, many surgeons are starting to perform this procedure with the tacit acceptance of a lengthy operation time because they often perceive LG to be a complicated technique inevitably subjected to the learning curve effect. A study by Kunisaki et al. \[[@pone.0114948.ref018]\] focused on one surgeon's surgical learning curve with LADG showed that the operating time was reduced to 230 mins after 60 cases. Lee et al. \[[@pone.0114948.ref019]\] reviewed 257 patients who received distal gastrectomies (included 136 LADGs and 120 ODGs); they found that the mean operation times were similar between the two groups. Our team performed its first LAG for early gastric cancer in April 2007. After "climbing up" the learning curve, we found that the operation time gradually decreased. The average operation time was 237 min after 218 patients \[[@pone.0114948.ref020]\], and decreased to 196 min after we completed 1380 cases \[[@pone.0114948.ref021]\]. Now, the average operation time is only 189.5 min. A stable team with a tacit understanding plays an important role in laparoscopic gastrectomy, making the operation easier and faster.

The incidence of postoperative complications is still the most frequently used surrogate marker of the ''quality'' of surgery. Laparoscopic gastrectomy for gastric cancer has gained popularity. However, reported morbidity rates for laparoscopic surgery vary from 6.1 to 25.4% \[[@pone.0114948.ref022]--[@pone.0114948.ref025]\]. A Korean laparoscopic gastrointestinal surgical society (KLASS) trial \[[@pone.0114948.ref022]\], which is a multicenter, prospective, randomized clinical trial, included 179 laparoscopic-assisted and 163 open distal gastrectomy patients, reported an 11.6% early morbidity for the LAG and 15.1% for the OG, with a mortality of 1% for the LAG. Kitano et al. \[[@pone.0114948.ref023]\] published a multicenter trial with 1294 patients undergoing laparoscopic gastrectomy. The mortality and morbidity rates found were 0% and 14.8%, respectively, and the rate of conversion to open surgery was 1.1%. These studies show that laparoscopic gastrectomy requires smaller incision, is less painful, enables rapid recovery, and results in decreased or no differences in the incidence of postoperative morbidity and mortality compared with open surgery. In this study, the postoperative morbidity and mortality were 13.6% and 0.3% respectively, in the LG group and 14.4% and 0.2%, respectively, in the OG group, with no significant differences (P\>0.05). Therefore, from these viewpoints, laparoscopic gastrectomy with extent lymph node dissection for gastric cancer is a safe and feasible choice.

Nowadays, more and more studies show that the procedure for gastrectomy with extensive lymph node dissection is well established and accepted as a standard practice for the treatment of AGC. So, besides the technical feasibility and favorable clinical outcomes of LG, the quality of lymphadenectomy is the most important factor in performing LG with extensive LN dissection. A Japanese study \[[@pone.0114948.ref025]\] found that adequate staging was possible for 86% of the patients who underwent LADG because more than 15 lymph nodes, the minimum requirement for tumor-node-metastasis staging, were retrieved. Song et al. \[[@pone.0114948.ref026]\] enrolled 75 patients who received standard D2 lymph nodes dissection (44 underwent LADG, and 31 underwent ODG), and found no significant differences in the total number of retrieved lymph nodes or node stations between the two groups. They suggested that LADG with D2 lymph node dissection is oncological compatible with OG. In the current study, as a way of comparing the oncology aspect of quality control between LG and OG groups, we compared the total number of retrieved lymph nodes, the positive LNs, and the number of LNs by their stages. Although, there was more positive LNs in LG group than that in OG group (P = 0.033), but this status disappeared when we compared the positive LNs by their stages. The results showed that there were comparable numbers of retrieved LNs between the LG group and OG group at each stage. The laparoscopic gastrectomy with extent lymph node dissection is technically possible, and the number of retrieved lymph node was sufficient for accurate staging.

The long-term oncologic result is very important to the use of laparoscopic gastrectomy. Nowadays, there are some multicenter, randomized controlled clinical trials, such as CLASS-01 by China laparoscopic gastrointestinal surgical society (CLASS), focused on the laparoscopic and open conventional surgery in the treatment of patients with local advanced gastric cancer. However, the confirmed results, including the oncologic outcomes, are still awaiting. Thus, before conducting a large multicenter phase III RCT comparing laparoscopic gastrectomy with open gastrectomy for AGC, it would be good to have the basis of a large retrospective study on the long-term outcomes for AGC after LG. Pak et al. \[[@pone.0114948.ref027]\] analyzed 714 consecutive patients who underwent LG for gastric cancer, and found that the 5-year overall survival rates were 96.4% in stage I, 83.1% in stage II, and 50.2% in stage III. Their results indicated that LG for gastric cancer had acceptable long-term oncologic outcomes. To date, oncologic outcomes after laparoscopic versus open gastrectomies for the treatment of AGC haves been reported in some studies \[[@pone.0114948.ref028]--[@pone.0114948.ref031]\]. Although oncologic safety seems to be identical between the groups, the sample size was relatively small and in some series the primary focus for analysis was on less advanced gastric cancers (some only included pT2 or pT3 patients). In the present study, we analyzed the surgical outcomes of a series of 2041 consecutive patients (74.7% patients with advanced gastric cancer) by laparoscopic group as compared with those treated using the open method. Although we showed that the long-term oncologic outcome was better for LG group than that in OG group. This survival benefit of laparoscopic group probably arose from heterogeneity of two groups. A comparison of the clinical factors between the two groups showed that lager tumor diameter, and more advanced cancers were dominant in patients who underwent open conventional surgery. After comparing the survival rates according to each stage, this benefit of survival disappeared. So our result showed that the long-term oncologic results showed that the laparoscopic approach was not statistically inferior to the open conventional approach for the treatment of gastric cancer, even in patients with advanced gastric cancer. Although the present study still has limitations due to the nature of our consecutive but retrospective study design and may have been biased by the patient selection criteria, the current data support the idea that laparoscopic gastrectomy is an oncologically safe treatment for advanced gastric cancer.

In conclusion, the surgical outcomes of LG for gastric cancer including AGC in the present study seem to be comparable to those previously reported. However, further randomized trials will provide valuable evidence for the oncological safety of laparoscopic gastrectomy for treatment of advanced gastric cancer.
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